vaccine
Big Pharma bets on University of Oxford vaccine after monkey tests
This screen grab taken from video issued by Britain’s Oxford University shows microbiologist Elisa Granato being injected as part of the first human trials in the UK for a potential coronavirus vaccine on April 23, 2020. The vaccine was developed by researchers at Oxford. less This screen grab taken from video issued by Britain’s Oxford …
Director of key federal vaccine agency says his departure was retaliation
Dr. Rick Bright had led BARDA, the Biomedical Advanced Research and Development Authority, since 2016 until Tuesday, when was reassigned to a narrower position. He also announced he will file a whistleblower complaint with the Department of Health and Human Services’ inspector general. “I believe this transfer was in response to my insistence that the …
Johnson & Johnson to begin clinical trials on coronavirus vaccine candidate
Johnson & Johnson said Monday human testing of its experimental vaccine for the coronavirus would begin by September and that it could be available for emergency use authorization in early 2021. J&J also said it has committed more than $1 billion of investment along with U.S. agency Biomedical Advanced Research and Development Authority, which is …
e-therapeutics PLC offers up its rapid screening technology in quest to find COVID-19 vaccine
Its “in silico”, or computer simulation platform has successfully found active compounds capable of protecting human cells in influenza e-therapeutics PLC () said it is gauging interest in its rapid screening technology as the pharma industry works to find an effective vaccine against COVID-19. Its “in silico”, or computer simulation platform has successfully found active …
Hopes of a coronavirus vaccine mount as three key biotech players make progress
The race is on to develop an immunization against COVID-19. Dozens of companies and public labs around the world are working to develop a vaccine to prevent the spread of the flu-like virus. Over the last 48 hours, three biotech companies, in particular, have been thrust into the spotlight for their promise: BioNTech, CureVac and …
Phase 1 Clinical Trial of Coronavirus Vaccine Commences
A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases …
Coronavirus: US volunteers test first vaccine
Image copyright Getty Images The first human trial of a vaccine to protect against pandemic coronavirus has started in the US. Four patients received the jab at the Kaiser Permanente research facility in Seattle, Washington, reports the Associated Press news agency. The vaccine cannot cause Covid-19 but contains a harmless genetic code copied from the …
Trump offers ‘large sums’ for exclusive access to coronavirus vaccine | US news
The Trump administration has offered a German medical company “large sums of money” for exclusive access to a Covid-19 vaccine, German media have reported. The German government is trying to fight off what it sees as an aggressive takeover bid by the US, the broadsheet Die Welt reports, citing German government circles. The US president …
Race to increase testing as COVID-19 spreads in U.S. and elsewhere
The coronavirus that emerged late last year and spread from central China was in almost 80 countries Wednesday morning, with outbreaks growing fast in South Korea, Italy, Iran and the United States. At least nine people have died of the COVID-19 disease in the U.S., all of them in Washington state and most of them …
COVID-19 kills 9 people in Washington state
CBS News medical contributor Dr. Tara Narula says many more Americans are going to be diagnosed with the new coronavirus as testing in the U.S. ramps up and the disease’s true spread is revealed, but the rising numbers shouldn’t worry the majority of people. “We’re really talking about those over 60, 70, 80 at risk,” …
